A Simpler Blood Test for Monitoring Kidney Transplant Recipients: “A Disrupting Innovation”

    loading  Checking for direct PDF access through Ovid

Excerpt

The management of chronic disease remains challenging on multiple fronts, requiring patients’ insight into their chronic disease; their compliance with medications and laboratory tests, regular follow-up with medical providers; and appropriate financial support through healthcare system. Kidney transplant recipients represent a distinctive model population with chronic disease where transplantation is limited by an inadequate organ supply, resulting in long wait times for a precious opportunity, the safeguarding of which then requires frequent, ongoing laboratory tests to monitor allograft function and drug levels. Transplantation is an immunological disease entity where the inability to achieve clinical transplant tolerance has left transplant physicians to rely solely on blood tests to assess allograft function and to manage therapeutic drug dosing. Kidney transplant recipients require regular testing of serum creatinine (sCr) and levels of cyclosporine A (CsA) or tacrolimus (TAC). Lapses in laboratory testing can lead to kidney graft dysfunction through missed opportunities to detect subtherapeutic dosing causing rejection and failure to identify drug toxicity. The processes of blood collection, testing methodologies, and reporting have not changed substantially over the past several decades.
The term “Disruptive Innovation” was coined by Clayton M. Christensen in 1995 to refer to a discovery “that creates a new market and value network and eventually disrupts an existing market and value network, displacing established market leading firms, products and alliances.” Unfortunately, the medical industry unlike other industries, in our opinion, has not welcomed “disruptive innovations.” However, in this issue of Transplantation, in their article entitled “Dried Blood Spot bio sampling to Follow TAC, cyclosporine A and creatinine levels in Kidney Transplant Patients”, Veenhof et al1 validate the use of Dried Blood Spot (DBS), a potential disruptive innovation, for the measurement of CsA, TaC, and sCr.
The technique of DBS has been in widespread use as a screening tool since the American microbiologist Robert Guthrie first introduced the “Guthrie card” in the 1960s to screen neonates for the metabolic disorder phenylketonuria.2 Recent advances have significantly improved the sensitivity and specificity of testing and have led to automation technology, allowing its use for an increasing range of tests, including screening for sickle cell and human immunodeficiency virus, and for measuring levels of vitamin D, TSH, lipids, testosterone, and various drugs.3 DBS sampling presents many important advantages over traditional whole blood sampling by venipuncture. DBS is less invasive than traditional phlebotomy, particularly important for patients with limited venous access due to the alterations and trauma of repeated phlebotomy and dialysis access. It offers the potential to collect samples outside of a laboratory facility without need for refrigeration, which could potentially decrease cost to the patient and allow appropriate timing of drug trough levels without need to consider laboratory business hours, transportation, and life constraints such as work, school, or childcare. DBS also presents less of a biohazard risk to handlers and is easier to transport than traditional laboratory vials and has the potential to be more economical both in terms of time and finances due to its ease, efficiency, rapid turnaround time for results and decreased need for laboratory equipment and personnel.
In a simple, innovative study, Veenhof et al1 examined the use of DBS in 210 paired samples from adult kidney transplant patients in a single transplant center. DBS samples were collected during routine visits and were allowed to dry for 1 to 7 days at room temperature, then stored in a −20°C freezer until analyzed. Linear regression analysis showed a significant correlation for sCr, TAC, and CsA levels between DBS and plasma derived from whole blood obtained by venipuncture.
    loading  Loading Related Articles